Publikationen, an denen er mitarbeitet JOSE LUIS LABANDEIRA GARCIA (67)

2020

  1. Aging-Related Overactivity of the Angiotensin/AT1 Axis Decreases Sirtuin 3 Levels in the Substantia Nigra, Which Induces Vulnerability to Oxidative Stress and Neurodegeneration

    The journals of gerontology. Series A, Biological sciences and medical sciences, Vol. 75, Núm. 3, pp. 416-424

2018

  1. Aging-related dysregulation in enteric dopamine and angiotensin system interactions: Implications for gastrointestinal dysfunction in the elderly

    Oncotarget, Vol. 9, Núm. 13, pp. 10834-10846

  2. Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson’s Disease Models

    Molecular Neurobiology, Vol. 55, Núm. 9, pp. 7297-7316

2017

  1. Brain renin-angiotensin system and microglial polarization: Implications for aging and neurodegeneration

    Frontiers in Aging Neuroscience, Vol. 9, Núm. MAY

  2. Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures

    Brain, Behavior, and Immunity, Vol. 62, pp. 277-290

2016

  1. Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration

    Frontiers in Neuroendocrinology, Vol. 43, pp. 44-59

2015

  1. Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation

    GLIA, Vol. 63, Núm. 3, pp. 466-482

  2. Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinsons Disease

    Neuroscientist, Vol. 21, Núm. 6, pp. 616-629

2014

  1. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA

    Neuropharmacology, Vol. 76, Núm. PART A, pp. 156-168

  2. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death

    Neuropharmacology, Vol. 85, pp. 1-8

  3. Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin

    GLIA, Vol. 62, Núm. 1, pp. 145-157

2013

  1. Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells

    Experimental Neurology, Vol. 250, pp. 384-396

  2. Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage

    Age, Vol. 35, Núm. 5, pp. 1675-1690

  3. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease

    Neurobiology of Disease, Vol. 58, pp. 209-219

2012

  1. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration

    Neurobiology of Aging, Vol. 33, Núm. 1, pp. 204.e1-204.e11

  2. Brain angiotensin and dopaminergic degeneration: Relevance to Parkinson’s disease

    American Journal of Neurodegenerative Diseases, Vol. 1, Núm. 3, pp. 226-244

  3. Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: Role of the brain angiotensin system

    Brain, Vol. 135, Núm. 1, pp. 124-138

  4. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: Effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease

    Journal of Neuroinflammation, Vol. 9

  5. Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors

    Neurobiology of Disease, Vol. 47, Núm. 2, pp. 268-279

  6. Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease

    Age, Vol. 34, Núm. 4, pp. 863-880